We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Muscle Relaxation Therapy With Odorant Cue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00208910
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : November 11, 2013
Sponsor:
Information provided by:
Emory University

Brief Summary:
A novel procedure for generalized anxiety disorder where an odorant cue is paired with the state of deep relaxation during training. It is hypothesized that by smelling the odor in an anxiety-provoking situation, the patient will more easily invoke a state of relaxation, providing greater relief from the distressing tension and worry that characterize GAD.

Condition or disease Intervention/treatment
Generalized Anxiety Disorder Anxiety Behavioral: Odorant Cue

Detailed Description:
We hypothesize that by presenting a novel odor to a patient in a state of deep relaxation, the odor will serve as a conditioned inhibitory stimulus, or safety signal, in anxiety-provoking situations. With the odor serving as a contextual cue for the state of relaxation.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Study of Enhancement of Progressive Muscle Relaxation Therapy for Generalized Anxiety Disorder Through Use Of An Odorant Cue.
Study Start Date : November 2003
Estimated Study Completion Date : May 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety
U.S. FDA Resources




Primary Outcome Measures :
  1. PSWQ

Secondary Outcome Measures :
  1. HAM-A


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • GAD without a comorbid active major psychiatric disorder.
  • GAD must be the primary active psychiatric disorder.
  • GAD determined via the Mini International Neuropsychiatric Interview (MINI).

Exclusion Criteria:

  • Significant medical illness that might interfere with the relaxation therapy or with training using the odorant.
  • Actively abusing alcohol.
  • Illicit substances.
  • Currently using rapid-acting anxiolytic agents (e.g. benzodiazepines, hydroxyzine).
  • Started an antidepressant, antipsychotic or mood stabilizing agent within three months of screening visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00208910


Locations
United States, Georgia
Emory University School of Medicine
Atlanta, Georgia, United States, 30329
Sponsors and Collaborators
Emory University
Investigators
Principal Investigator: Philip T Ninan, MD Emory University

ClinicalTrials.gov Identifier: NCT00208910     History of Changes
Other Study ID Numbers: 0860-2003
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: November 11, 2013
Last Verified: November 2013

Keywords provided by Emory University:
Anxiety
Mental Health

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders